Adage Capital Partners
RVMD icon

Adage Capital Partners’s Revolution Medicines RVMD Stock Holding History

Adage Capital Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$533M Buy
5,475,611
+3,270,056
+148% +$330M 0.82% 15
2025
Q4 		$176M Buy
2,205,555
+1,463,155
+197% +$95.9M 0.27% 65
2025
Q3 		$34.7M Buy
742,400
+345,000
+87% +$13.5M 0.05% 320
2025
Q2 		$14.6M Buy
397,400
+3,400
+0.9% +$131K 0.02% 522
2025
Q1 		$13.9M Sell
394,000
-256,000
-39% -$10.4M 0.03% 504
2024
Q4 		$28.4M Buy
650,000
+360,000
+124% +$18.2M 0.05% 346
2024
Q3 		$13.2M Buy
290,000
+120,000
+71% +$5.23M 0.02% 557
2024
Q2 		$6.6M Sell
170,000
-30,000
-15% -$1.12M 0.01% 677
2024
Q1 		$6.45M Buy
+200,000
New +$5.93M 0.01% 668
2023
Q4 		– Sell
-30,000
Closed -$830K – 920
2023
Q3 		$830K Buy
+30,000
New +$890K ﹤0.01% 770
2020
Q2 		– Sell
-25,000
Closed -$548K – 793
2020
Q1 		$548K Buy
+25,000
New +$692K ﹤0.01% 698

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners's RVMD Position: Q1 2026 in Review

Adage Capital Partners increased its Revolution Medicines (RVMD) stake by 148% in Q1 2026, buying an estimated $330M and bringing the position to 5,475,611 shares worth $533M. The position accounts for 0.82% of the portfolio, ranked #15.

Adage Capital Partners first reported a position in RVMD in Q1 2020 and has held it in 11 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Adage Capital Partners held 5,475,611 shares of Revolution Medicines worth $533M as of Q1 2026.
  • Adage Capital Partners bought 3,270,056 Revolution Medicines shares in Q1 2026, an estimated $330M.
  • Revolution Medicines made up 0.82% of Adage Capital Partners's portfolio in Q1 2026, its #15 holding.
  • Adage Capital Partners first reported a position in Revolution Medicines in Q1 2020 and has held it in 11 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.